AbbVie Inc  

(Public, NYSE:ABBV)   Watch this stock  
Find more results for NYSE:ABBV*
65.06
-1.11 (-1.68%)
After Hours: 65.03 -0.03 (-0.05%)
Aug 24, 4:54PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 64.84 - 66.53
52 week 45.45 - 68.12
Open 66.31
Vol / Avg. 8.55M/6.87M
Mkt cap 104.62B
P/E 18.65
Div/yield 0.57/3.50
EPS 3.49
Shares 1.63B
Beta 1.50
Inst. own 72%
Oct 28, 2016
Q3 2016 AbbVie Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jul 29, 2016
Q2 2016 AbbVie Inc Earnings Release
Jul 29, 2016
Q2 2016 AbbVie Inc Earnings Call - Webcast
Jun 9, 2016
AbbVie Inc at Goldman Sachs Global Healthcare Conference
Jun 8, 2016
AbbVie Inc at Jefferies Healthcare Conference
Jun 3, 2016
AbbVie Inc R&D Day - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin 24.95% 22.50%
Operating margin 37.00% 32.97%
EBITD margin - 38.09%
Return on average assets 10.68% 12.77%
Return on average equity 125.60% 180.90%
Employees 28,000 -
CDP Score - 89 D

Address

1 N Waukegan Rd
NORTH CHICAGO, IL 60064-1802
United States - Map
+1-847-9327900 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions. AbbVie also has a pipeline of new medicines, including over 50 compounds or indications, such as immunology, virology/liver disease, oncology, neurological diseases and women's health. Its product portfolio includes HUMIRA, IMBRUVICA, HCV products, additional virology products, metabolics/hormones products, endocrinology products and other products.

Officers and directors

Richard A. Gonzalez Chairman of the Board, Chief Executive Officer
Age: 62
Bio & Compensation  - Reuters
William J. Chase Executive Vice President, Chief Financial Officer
Age: 48
Bio & Compensation  - Reuters
Michael Severino M.D. Executive Vice President - Research & Development, Chief Scientific Officer
Age: 50
Bio & Compensation  - Reuters
Laura J. Schumacher Executive Vice President, External Affairs, General Counsel and Corporate Secretary
Age: 52
Bio & Compensation  - Reuters
Carlos Alban Executive Vice President - Commercial Operations
Age: 53
Bio & Compensation  - Reuters
Henry O. Gosebruch Executive Vice President, Chief Strategy Officer
Age: 43
Bio & Compensation  - Reuters
Timothy J. Richmond Senior Vice President - Human Resources
Age: 49
Bio & Compensation  - Reuters
Azita Saleki-Gerhardt Ph.D. Senior Vice President - Operations
Age: 52
Bio & Compensation  - Reuters
Thomas A. Hurwich Vice President, Controller
Age: 55
Bio & Compensation  - Reuters
Robert J. Alpern M.D. Independent Director
Age: 65
Bio & Compensation  - Reuters